Aniridia and Boston KPro: Is It a Long-Term Option?

被引：0

作者：

Knutsson K.A. ^{[1
]}

Rama P. ^{[2
]}

机构：

[1] Department of Ophthalmology, San Raffaele Scientific Institute, Milan

[2] Cornea and Ocular Surface Unit, San Raffaele Scientific Institute, Via Olgettina 60, Milan

来源：

Current Ophthalmology Reports | 2016年 / 4卷 / 3期

关键词：

Aniridia; Aniridic keratopathy; Boston keratoprosthesis; Boston KPro; Keratoprosthesis; KPro;

D O I：

10.1007/s40135-016-0105-0

中图分类号：

学科分类号：

摘要：

Purpose of Review: Aniridia is a complex ocular disorder that causes limbal stem cell deficiency determining progressive aniridic keratopathy and the loss of corneal transparency. Allogeneic limbal stem cell transplantation followed by penetrating keratoplasty can stabilize the ocular surface but requires prolonged systemic immunosuppression. The type-1 Boston Keratoprosthesis can be a valid alternative allowing faster visual recovery without the need for systemic immunosuppression. Recent Findings: Several studies have reported good visual outcomes and good retention rates for keratoprosthesis in aniridic patients. Nonetheless, concerns still exist regarding complications that might lead to irreversible loss of function, such as glaucoma progression or intraocular infection. Other complications include retroprosthetic membrane formation, hypotony, and device extrusion. The presence of macular pathology and prevalence of glaucoma are two factors that may affect final visual acuity outcomes in aniridic patients. Summary: Implantation of the type-1 Boston Keratoprosthesis for aniridic keratopathy has shown promising results. However, further studies are needed to provide more evidence regarding long-term survival and complications. © 2016, Springer Science + Business Media New York.

引用

页码：154 / 158

页数：4

共 34 条

[1]

Nelson L.B., Spaeth G.L., Nowinski T.S., Margo C.E., Jackson L., Aniridia: a review, Surv Ophthalmol, 28, 6, pp. 621-642, (1984)

[2]

Gupta S.K., De B.I., Tremblay F., Guernsey D.L., Neumann P.E., Genotype/phenotype correlations in aniridia, Am J Ophthalmol, 126, 2, pp. 203-210, (1998)

[3]

Kokotas H., Petersen M.B., Clinical and molecular aspects of aniridia, Clin Genet, 77, 5, pp. 409-420, (2010)

[4]

Bakhtiari P., Chan C., Et al., Surgical and visual outcomes of the type I Boston Keratoprosthesis for the management of aniridic fibrosis syndrome in congenital aniridia, Am J Ophthalmol, 153, 5, pp. 967-971, (2012)

[5]

Miller S.J., Lavker R.M., Sun T.T., Keratinocyte stem cells of cornea, skin, and hair follicle, stem cells, pp. 331-362, (1997)

[6]

Muller L.J., Marfurt CF et al. [Erratum to: Muller LJ, Marfurt CF et al. Corneal nerves: structure, contents and function, Exp Eye Res, 76, pp. 521-542, (2003)

[7]

Jastaneiah S., Al Rajhi A.A., Association of Aniridia and dry eyes, Ophthalmology, 112, pp. 1535-1540, (2005)

[8]

Kruse F.E., Classification of ocular surface disease, Ocular surface disease: medical and surgical management, pp. 16-36, (2002)

[9]

Lopez-Garcia J.S., Rivas L., Et al., Autologous serum eyedrops in the treatment of aniridic keratopathy, Ophthalmology, 115, pp. 262-267, (2008)

[10]

Nakamura T., Inatomi T., Et al., Phenotypic investigation of human eyes with transplanted autologous cultivated oral mucosal epithelial sheets for severe ocular surface diseases, Ophthalmology, 114, pp. 1080-1088, (2007)

← 1 2 3 4 →